## **EXHIBIT A**

						National Library of Medicine e National Institutes of Health [Sign In] [Register			
All Databases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
earch PubMed		for		0.10			Gø	Clear	
Limits Previe	w/Index	History C	lipboard	Details					
					227	2025			
splay AbstractP	ius	▼ She	ow 20	Sort by	Seno	to 🔀			
ੀ ਗੋ:1 Review: (	े ख्या								
- Novion.	10000								
1: J Pharmacobi	odyn. 1986	Oct;9(10):861-4							Lini
	(1000)								
Antitumor activ			btained fro	m liquid	F	Related Lir	ıks		
cultured myceli	um of Grifo	la frondosa.						rties and an	
Ohno N, Adachi '	/ Suzuki I	Oikawa S Sate	K Oheau	n M. Vadom	00 T			Pham Bull (To	• •
								vsaccharide UPharmacobio	
'he antitumor acti rom liquid culture:								nor effect of	•
709-1715 (1986)								JPharmacobio	
intraperitoneal (i.p.) administration (100-200 micrograms/mouse/d X 5) at						Distribution of grifolan NMF-5N (I/B), a chemically modified [J Pharmacobiodyn. 1988			
days 1 to 9 from the tumor transplantation, grifolan LE showed marked inhibitory activity on the growth of solid form sarcoma 180 in ICR mice.									
Significant activity was also observed in intravenous (i.v.) or intratumoral						Change of biological activities of (13)-beta-D [Chem Pharm Bull (Tokyo), 1990			
i.t.) administration	s. However,	the oral (p.o.) a	dministratio	n of grifolan		(13)-DE	ia-D [Clean	Presin bull(10	куој. 1990
was not effective. I.p. administration of grifolan LE at a dose of 100 micrograms/mouse/d X 5 before the tumor transplantation showed						See all Related Articles			
ignificant inhibitio					vsh te				
11 to +19 was al									
orm of sarcoma 1									
n vitro did not affe arcoma 180 by a									
ame tumor cell. F					e				
ctivity of grifolan									

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Apr 30 2007 04:56:27